Incorporating strong operational momentum and healthy mid-to-long term outlook
30/05/25 -"Faes Farma (+25% ytd) has been one of the best performing European pharmas in our coverage this year, driven by the strength of its operations and perhaps to an extent, the absence of direct US ..."
Pages
49
Language
English
Published on
30/05/25
You may also be interested by these reports :
02/06/25
We have updated our estimates with the latest figures. The EPS has improved due to lower-than-expected R&D costs. This improvement is supported by ...
01/06/25
CureVac has repositioned itself as an early-stage biotech company following the out-licensing of its infectious disease portfolio to GSK. The deal ...
30/05/25
Faes Farma (+25% ytd) has been one of the best performing European pharmas in our coverage this year, driven by the strength of its operations and ...
30/05/25
After some of the key patent expiries at the start of this decade, Lundbeck has been growing at a healthy pace, on the back of its four main ...